Macrae Sandy 4
4 · SANGAMO THERAPEUTICS, INC · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Sangamo (SGMO) CEO Sandy Macrae Sells Shares for Tax Withholding
What Happened
Sandy Macrae, President, CEO and Director of Sangamo Therapeutics (SGMO), surrendered a total of 38,928 shares to the company to satisfy mandatory tax withholding tied to RSU vesting. On Feb 24, 2026 she surrendered 5,291 shares at $0.4725/share (reported proceeds $2,500) and on Feb 25, 2026 she surrendered 33,637 shares at $0.47/share (reported proceeds $15,809). These transactions are reported as dispositions for tax withholding purposes and are not open‑market sales.
Key Details
- Transaction dates and prices: Feb 24, 2026 — 5,291 shares at $0.4725; Feb 25, 2026 — 33,637 shares at $0.47.
- Reported proceeds: $2,500 (Feb 24) and $15,809 (Feb 25); total ≈ $18,309.
- Transaction code: F — shares surrendered to the issuer for mandatory tax withholding (not a discretionary sale).
- Source of shares: vested restricted stock units (RSUs). Footnotes indicate these include 9,456 shares from a Feb 24, 2023 RSU grant and portions of a Feb 25, 2025 RSU RSU grant (the Feb 25, 2026 vesting installment included 60,113 shares; remaining portions vest in scheduled quarterly installments), with vesting subject to continuous service and plan terms.
- Shares owned after the transactions: not specified in the filing.
- Filing: Form 4 filed Feb 26, 2026; transactions reported promptly (no late filing flag).
Context
These were tax‑withholding dispositions tied to RSU vesting (common executive administrative transactions). Because the shares were surrendered to cover taxes under the company’s equity plan, these do not represent an open‑market sale or a discretionary trade and should not be interpreted as a new buy/sell signal by the insider.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2]2026-02-24$0.47/sh−5,291$2,500→ 1,941,293 total - Tax Payment
Common Stock
[F3][F4]2026-02-25$0.47/sh−33,637$15,809→ 1,907,656 total
Footnotes (4)
- [F1]Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F2]Includes: (a) 9,456 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
- [F3]Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F4]Includes: 60,113 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 281,250 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.